Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

Kynam Capital Management, LP

CIK 0001907884
$1.62B
Reported AUM
37
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · Kynam Capital Management, LP · Q1 2026

AI · grounded in 13F

Kynam Capital Management, LP closed its position in TYRA for a reduction of $41.1M. The fund also exited positions in CGON and DVAX, totaling $39.3M and $21.2M respectively. On the buy side, the fund established new positions in URGN for $40.4M and LEGN for $28.5M. Additionally, it increased its stake in TVTX by 368%.

Portfolio · Q1 2026

SNDX$188.1MCLDX$185.3MPCVX$169.8MCOGT$155.4MVERA$136.7MBEAM$87.7MTVTXCTMXBCRXVRDNCGEMURGNOther$371.0MKL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1SNDXSYNDAX PHARMACEUTICALS INC$19.260.21%92.38%9.78%$188.1M11.60%HELD
2CLDXCELLDEX THERAPEUTICS INC NEW$37.790.75%70.78%-28.02%$185.3M11.43%HELD
3PCVXVAXCYTE INC$54.542.94%60.21%101.68%$169.8M10.48%HELD
4COGTCOGENT BIOSCIENCES INC$40.602.60%257.28%391.91%$155.4M9.59%HELD
5VERAVERA THERAPEUTICS INC$32.42-0.28%55.85%121.51%$136.7M8.43%HELD
6BEAMBEAM THERAPEUTICS INC$25.72-1.15%37.07%-76.73%$87.7M5.41%HELD
7TVTXTRAVERE THERAPEUTICS INC$56.361.44%260.59%158.18%$72.0M4.44%HELD
8CTMXCYTOMX THERAPEUTICS INC.$3.211.42%37.02%-37.11%$70.6M4.35%HELD
9BCRXBIOCRYST PHARMACEUTICALS INC$9.27-2.78%16.54%-41.80%$54.1M3.34%HELD
10VRDNVIRIDIAN THERAPEUTICS INC$19.63-1.26%14.19%48.58%$45.8M2.83%HELD
11CGEMCULLINAN THERAPEUTICS INC$17.471.51%128.68%-37.85%$44.3M2.73%HELD
12URGNUROGEN PHARMA LTD$40.901.10%110.95%132.26%$40.4M2.49%HELD
13KALVKALVISTA PHARMACEUTICALS INC$36.7M2.26%HELD
14APLSUSDAPELLIS PHARMACEUTICALS INC$33.2M2.05%HELD
15LEGNLEGEND BIOTECH CORP$18.930.42%-52.04%-51.40%$28.5M1.76%HELD
16MBXMBX BIOSCIENCES INC$66.003.19%378.44%187.27%$27.9M1.72%HELD
17IMCRIMMUNOCORE HLDGS PLC$33.811.17%2.33%-2.31%$26.7M1.65%HELD
18STROSUTRO BIOPHARMA INC$24.474.93%187.90%-89.26%$21.7M1.34%HELD
19RVMDREVOLUTION MEDICINES INC$188.764.33%393.91%521.93%$20.2M1.24%HELD
20BNRBURNING ROCK BIOTECH LTD$8.890.79%55.56%-95.27%$19.8M1.22%HELD
21SLNOSOLENO THERAPEUTICS INC$18.7M1.16%HELD
22NRIXNURIX THERAPEUTICS INC$23.29-1.31%110.51%-27.80%$18.5M1.14%HELD
23PHVSPHARVARIS N V$33.623.05%67.35%65.78%$18.1M1.12%HELD
24EVMNEVOMMUNE INC$11.110.54%-39.65%-35.11%$14.4M0.89%HELD
25RLAYRELAY THERAPEUTICS INC$18.842.56%461.61%-41.09%$14.2M0.87%HELD
26GERNGERON CORP$1.410.71%19.66%-3.45%$10.2M0.63%HELD
27ENGENE HOLDINGS INC$9.2M0.57%HELD
28DSGNDESIGN THERAPEUTICS INC$12.503.99%229.32%-19.97%$8.3M0.51%HELD
29WVEWAVE LIFE SCIENCES LTD$5.57-4.22%-34.88%-11.22%$7.0M0.43%HELD
30CLYMCLIMB BIO INC$12.352.02%752.07%-31.28%$6.9M0.42%HELD
31AMRNAMARIN CORP PLC$14.15-0.07%$6.8M0.42%HELD
32BHVNBIOHAVEN LTD$13.30-0.97%$5.9M0.37%HELD
33PRLDPRELUDE THERAPEUTICS INC$4.801.91%$5.4M0.34%HELD
34CRBUCARIBOU BIOSCIENCES INC$1.501.70%$4.8M0.29%HELD
35ALECALECTOR INC$1.648.22%$4.3M0.27%HELD
36PRQRPROQR THRAPEUTICS N V$1.740.64%$2.5M0.16%HELD
37CADLCANDEL THERAPEUTICS INC$9.723.40%$980K0.06%HELD

Source: SEC EDGAR · accession 0001907884-26-000007. 13F discloses long positions only — shorts, foreign equities, and options are excluded.